JP2004315470A - Pharmaceutical preparation containing sodium iodide - Google Patents
Pharmaceutical preparation containing sodium iodide Download PDFInfo
- Publication number
- JP2004315470A JP2004315470A JP2003114498A JP2003114498A JP2004315470A JP 2004315470 A JP2004315470 A JP 2004315470A JP 2003114498 A JP2003114498 A JP 2003114498A JP 2003114498 A JP2003114498 A JP 2003114498A JP 2004315470 A JP2004315470 A JP 2004315470A
- Authority
- JP
- Japan
- Prior art keywords
- iodine
- sodium iodide
- weight
- aids
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 title claims abstract description 76
- 235000009518 sodium iodide Nutrition 0.000 title claims abstract description 25
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract description 52
- 239000011630 iodine Substances 0.000 claims abstract description 52
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 52
- 238000002360 preparation method Methods 0.000 claims abstract description 24
- 208000030507 AIDS Diseases 0.000 claims abstract description 15
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 15
- 239000012670 alkaline solution Substances 0.000 claims abstract description 9
- 201000011510 cancer Diseases 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 5
- 230000000069 prophylactic effect Effects 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 239000000243 solution Substances 0.000 abstract description 9
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 238000002347 injection Methods 0.000 abstract description 6
- 239000007924 injection Substances 0.000 abstract description 6
- 230000009471 action Effects 0.000 abstract description 2
- 230000003449 preventive effect Effects 0.000 abstract 1
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 18
- 238000012360 testing method Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 11
- 230000002265 prevention Effects 0.000 description 8
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 231100000572 poisoning Toxicity 0.000 description 5
- 230000000607 poisoning effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229920000153 Povidone-iodine Polymers 0.000 description 3
- 239000012830 cancer therapeutic Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 229960001621 povidone-iodine Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 230000003253 viricidal effect Effects 0.000 description 2
- MGFWQHJISKJHMB-UHFFFAOYSA-N 1-iodopropane-1,2,3-triol Chemical compound OCC(O)C(O)I MGFWQHJISKJHMB-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WHRZCXAVMTUTDD-UHFFFAOYSA-N 1h-furo[2,3-d]pyrimidin-2-one Chemical compound N1C(=O)N=C2OC=CC2=C1 WHRZCXAVMTUTDD-UHFFFAOYSA-N 0.000 description 1
- 238000000846 Bartlett's test Methods 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000006173 Larrea tridentata Nutrition 0.000 description 1
- 244000073231 Larrea tridentata Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- -1 alkali metal salt Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 229960002126 creosote Drugs 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940109426 iodine pill Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- FJWLWIRHZOHPIY-UHFFFAOYSA-N potassium;hydroiodide Chemical compound [K].I FJWLWIRHZOHPIY-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 206010056873 tertiary syphilis Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【０００１】
【産業上の利用分野】
本発明は、抗ウイルス剤或いは抗癌剤として優れた予防及び治療効果を有するヨウ化ナトリウムを含有する弱アルカリ性溶液からなる新規なヨウ化ナトリウム製剤に関する。
【０００２】
【従来の技術】
ヨウ素或いはヨウ化カリウム、ヨウ化ナトリウム等を含有するヨウ素製剤は、周知のように、古くから皮膚表面の一般消毒、創傷、潰瘍の殺菌・消毒等に広く用いられており、その後もその製剤の改良工夫が続けられ、多くの特許出願がなされてきている。また、特にヨウ素の有機複合化合物であるヨードグリセリン、ポリビニルアルコールヨウ素或いはポビドンヨードなどを含有するヨウ素製剤は、皮膚表面の一般消毒のほか、咽頭炎、扁桃炎等の口腔創傷の感染予防、口腔内消毒に或いは角膜ヘルペス、洗眼殺菌などの予防・治療剤として市販されている。最近では、ヨウ素成分として、ポビドンヨードを含有せしめたヨウ素製剤の開発が多くなされるようになってきており、ゼラチンおよび糖類等にポビドンヨードを含有せしめた外用剤も提案されている（例えば、特許文献１、２参照）。また、殺ウイルス効果に着目して、ヨウ素分として０．６〜０．０１重量％のヨウ素及び／又はヨウ素のアルカリ金属塩を含有する膣および口腔粘膜用水性消毒液が提案されている（例えば、特許文献３参照）。
【０００３】
一方、医師による治療に用いられるヨウ素剤としてはヨウ素カリウム丸（ヨウ素分３８ｍｇ／錠）、ヨウ化カリウム液（ＫＩ液ヨウ素分１０ｍｇ）、ヨウ素レシチン（５０〜１００μｇ／錠）等があり、甲状腺機能亢進症を伴う甲状腺腫瘍（ヨウ化カリウム１日５〜５０ｍｇ）、気管支炎及び喘息に伴う喀痰喀出困難症・第三期梅毒（ヨウ化カリウム１日０．３〜２．０ｇ）等に使用されている。また、アイソトープ１３１Ｉ放射性ヨード治療剤として甲状腺治療に活用され、更に原子力災害時における安定ヨウ素剤（放射線の内部被爆による甲状腺癌の予防：１日服用量ヨウ化カリウム１００ｍｇ−ヨウ化カリウム丸２丸、ヨウ素分７６ｍｇ−ＷＨＯは１００ｍｇ）として推奨されている（例えば、非特許文献１参照）。
【０００４】
牧野民蔵博士および飯島登博士は、１９２０年頃から１９３５年頃にかけての研究成果として、タラ肝油、竜脳、クレオソートおよびヨウ素から製造されたヨウ素製剤、通称「マキノヨードもしくはネオ・マキス」は、高血圧症、血管硬化症から結核、喘息、胃潰瘍、白血病等の他、癌・エイズ等多岐に渡る薬剤効果があると報告されている。ヨードの癌（乳癌）増殖抑制効果も期待されるとの報告もある（例えば、非特許文献２参照）。
【０００５】
しかし、ヨウ素の摂取基準は所要量１５０μｇ／日、許容上限摂取量３ｍｇ／日（第６次日本人の栄養所要量の食事摂取基準）であり、服用ヨウ素薬剤の一日有効ヨウ素量はその利益と不利益（ヨウ素中毒症）を考慮して微量使用であり、最大で１００ｍｇ（ＷＨＯや多くの諸外国における奨励服用量−安定ヨウ素剤の場合）とされている。ヨウ素は反応性が高く、人体に対して非常に強い毒性を示すことから劇薬に指定されており、従来の消毒薬或いは止血薬（ヨードチンキ等）用のヨウ素製剤においても１％以下の含有量のものとして使用され、また服用或いは注射用としても大量投与・長期運用による副作用の可能性のため慎重投与すべきとし、１日摂取量最大１００ｍｇ以下で使用されている。このようなことから、ヨウ素には種々の薬剤効果が期待されていながら、それらに向けた癌・エイズ治療のための服用或いは注射用ヨウ素製剤は未だ開発されていない。
【０００６】
【特許文献１】
特開平９−４０５６３号公報
【特許文献２】
特開２００１−１２２７９０号公報
【特許文献３】
特開平６−１７２１９２号公報
【非特許文献１】
「原子力災害時における安定ヨウ素剤予防服用考え方について」
平成１４年４月 原子力安全委員会 原子力施設等防災専門部会
【非特許文献２】
日本癌治療学会誌、１９９４年３月号
【０００７】
【発明が解決しようとする課題】
本発明の目的は、抗（ｏｒ殺）ウイルスおよび癌治療効果を有し、且つ、ヨード中毒等の副作用のない注射剤としてあるいは経口投与することができる液状のヨウ素製剤を開発することにある。
【０００８】
【課題を解決するための手段】
本発明者らは、上記課題を解決するため鋭意研究を進めた結果、１）経口摂取の場合ヨウ素分として１．０〜１．５重量％相当量のヨウ化ナトリウムを含有する服用液は、一日摂取量１００ｍｇを超えても、副作用（ヨード中毒）がなく、極めて高い抗癌効果を有することを見出した。また、２）注射摂取の場合ヨウ素分として１．０重量％〜１．５重量％相当量のヨウ化ナトリウムを含有するエイズ治療用注射液剤も、一日摂取量１００ｍｇを超えても、副作用（ヨード中毒）がなく、極めて高い抗（殺）エイズ・ウイルス効果を有することを見出した。
【０００９】
すなわち、本発明は、下記１）記載のヨウ化ナトリウム含有製剤、２）記載の癌の予防及び治療剤及び３）記載のエイズの予防及び治療剤を提供するものである。
１）ヨウ素分として１．０重量％〜１．５重量％相当量のヨウ化ナトリウムを含有する弱アルカリ性溶液からなるヨウ化ナトリウム含有製剤。
２）ヨウ素分として１．０重量％〜１．５重量％相当量のヨウ化ナトリウムを含有する弱アルカリ性溶液からなる癌の予防及び治療剤。
３）ヨウ素分として１．０重量％〜１．５重量％相当量のヨウ化ナトリウムを含有する弱アルカリ性溶液からなるエイズの予防及び治療剤。
以下、本発明を詳細に説明する。
【００１０】
【発明の実施の形態】
ミネラル水の電気分解によって生成される電解水であるアルカリイオン水にヨウ化ナトリウム塩（純度９９．９９％）を混入させヨウ化ナトリウム溶液を調製する。この溶液のｐＨは７〜８である。本発明においては、上記アルカリイオン水（９８．０ｃｃ）にヨウ化ナトリウム２．０ｇ（ヨウ素分１ｇ・ナトリウム分１ｇ）を加えて調製したヨウ素分として１．０％含有する液剤を用いた。当該液剤を癌の予防或いは治療用には２００ｃｃ／日服用し、エイズの予防或いは治療用には２０ｃｃ／日静脈投与した。
【００１１】
なお、本発明のヨウ化ナトリウム含有製剤には、その作用を損なわない範囲で、液体製剤に一般的に添加されている各種アミノ酸、ブドウ糖或いはビタミン剤等の高カロリー化剤、その他安定化剤、無痛化剤或いは少量の着色剤等を加えることは何ら差し支えない。
以下に試験例を示し、本発明のヨウ化ナトリウム含有製剤がエイズおよび癌に対する治療効果を有することを説明する。
【００１２】
【試験例】
試験例１：癌治療効果試験
上記の様に調製した本発明のヨウ化ナトリウム含有製剤を用いて下記条件により癌治療効果試験を行なった。その試験の結果を表１に示す。
１）治験患者：女性４２才
２）病名：右部の乳癌（スキルス性腫瘍：約４ｃｍ径）
３）投与法：癌治療用ヨウ素液剤５０ｃｃを１日４回（２００ｃｃ／日）服用
４）治験期間：１７ヶ月
【００１３】
【表１】
表１の結果から明らかように、１７ヶ月間の（長期）投与により、腺癌腫瘍マーカーであるＣＥＡ（基準値低値０．０〜基準値高値５．０）は１４．５から５．２に、ＣＡ１９−９（基準値低値０．０〜基準値高値３７．０）は、１，０７７から５３に激減し、それぞれ基準値近くまで下降すると同時に、癌の転移は認められなかった。３月後のＣＴ検査で当初径４ｃｍの乳腫瘍は約２センチにまで縮小し、また、パンパンに張っていた乳房が普通の状態に回復した。
また、患者は、試験期間中通常の日常生活をおくり体調の好転がみられ、血液検査値（血中タンパク、白血球、肝機能指標等）も正常値を維持し、副作用（ヨード中毒）の発生も認められなかった。
【００１５】
試験例２：エイズ治療試験
上記のようにして調製した本発明のヨウ化ナトリウム含有製剤を用いて下記条件によりエイズ治療試験を行なった。その試験の結果を表２に示す。
１）測定法：Ｂａｙｅｒ ＨＩＶ−１ ＲＮＡ ３．０ Ａｓｓａｙ （ｂＤＮＡ）法
２）治験患者：男性２４才
３）投薬：エイズ治療用ヨード剤２０ｃｃ／日を静脈注射
４）治験期間：２０日間
【００１６】
【表２】
表２の結果から明らかなように、２０日間の投与によりＨＩＶ‐ＲＮＡ（遺伝子）は、ほぼ５０％という大幅な減少（殺ウイルス効果）が見られた（ＨＩＶ粒子量としては表１の１／２）。また、２０日間の投与期間中および投与後において副作用等の兆候は認められなかった。
【００１８】
試験例３：動物毒性試験
次の条件により、ラットにおける毒性試験を行なった。
１）被験物質：ヨード剤（投与量 ２ｍｌ／Ｋｇ×体重）、対照物質：精製水
２）使用動物：ＳＰＦラット１０匹
３）観察期間：１４日
４）測定法：一般状態観察と体重値‐Ｂａｒｔｌｅｔｔ検定法、危険率１０％以下
その結果は、▲１▼いずれの動物も死亡せず、一般状態にも異常は認められない、▲２▼一元配置分散分析法による被験および対照物質の比較分析では体重推移に有意差は認められない。
以上の結果から、本発明のヨウ化ナトリウム含有製剤の毒性は極めて低く、そのＬＤ５０値（急性毒性）は２０００ｍｇ／Ｋｇを超えると判断された。
【００１９】
【発明の効果】
以上詳細に説明したように、本発明により、従来のヨウ素製剤を超えるヨウ素含有量でありながら、副作用が極めて低く、しかも、注射或いは経口投与することができる画期的なエイズ治療効果および癌治療効果を有する新規なヨウ素含有製剤が提供された。
したがって、本発明のヨウ化ナトリウム含有製剤は、安全性が高く、癌およびエイズの予防および治療に大きな効果が期待される。[0001]
[Industrial applications]
The present invention relates to a novel sodium iodide preparation comprising a weak alkaline solution containing sodium iodide, which has excellent prophylactic and therapeutic effects as an antiviral or anticancer agent.
[0002]
[Prior art]
As is well known, iodine preparations containing iodine or potassium iodide, sodium iodide, etc. have been widely used for general disinfection of skin surface, sterilization / disinfection of wounds, ulcers, etc. since ancient times. Improvements have been made and many patent applications have been filed. In particular, iodine preparations containing iodine organic complex compounds such as iodoglycerin, polyvinyl alcohol iodine or povidone iodine, are used for general disinfection of the skin surface, as well as for prevention of infection of oral wounds such as pharyngitis and tonsillitis, and oral disinfection. Or as a prophylactic / therapeutic agent for corneal herpes, eyewash disinfection and the like. Recently, iodine preparations containing povidone-iodine as an iodine component have been increasingly developed, and external preparations containing povidone-iodine in gelatin, saccharides and the like have been proposed (for example, Patent Document 1). , 2). In addition, focusing on the virucidal effect, an aqueous disinfecting solution for vaginal and oral mucosa containing 0.6 to 0.01% by weight of iodine and / or an alkali metal salt of iodine has been proposed (e.g., iodine content). And Patent Document 3).
[0003]
On the other hand, iodine agents used for treatment by doctors include potassium iodine pill (38 mg iodine content / tablet), potassium iodide solution (KI solution iodine content 10 mg), iodine lecithin (50-100 μg / tablet) and the like. It is used for thyroid tumors with hypertension (potassium iodide 5 to 50 mg per day), bronchitis and sputum dysfunction associated with asthma, tertiary syphilis (potassium iodide 0.3 to 2.0 g per day), etc. ing. It is also used in the treatment of thyroid as a therapeutic agent for radioactive iodine of isotope 131I. In addition, a stable iodine agent (prevention of thyroid cancer by internal exposure to radiation: daily dose of potassium iodide 100 mg-potassium iodide maru 2) at the time of a nuclear disaster It is recommended as an iodine content of 76 mg-WHO is 100 mg) (for example, see Non-Patent Document 1).
[0004]
Dr. Tamzo Makino and Dr. Noboru Iijima reported that as a result of research from around 1920 to around 1935, iodine preparations made from cod liver oil, dragon brain, creosote, and iodine, commonly known as “Makinoiod or Neo-Makis”, were used for hypertension, vascular It has been reported that there are a wide variety of drug effects such as sclerosis, tuberculosis, asthma, gastric ulcer, leukemia, etc. as well as cancer and AIDS. There is also a report that iodine is expected to have a cancer (breast cancer) growth inhibitory effect (for example, see Non-Patent Document 2).
[0005]
However, the standard of iodine intake is the required amount of 150 μg / day, the upper limit of allowable intake is 3 mg / day (the standard of dietary intake for the nutritional requirement of the 6th Japanese), and the daily effective iodine amount of the iodine drug taken is the benefit. In view of the disadvantages and disadvantages (iodine poisoning), it is used in trace amounts, and is set at a maximum of 100 mg (in the case of WHO and recommended dosage in many foreign countries-stable iodine agent). Iodine has been designated as a powerful drug because of its high reactivity and extremely strong toxicity to the human body. Even in conventional iodine preparations for disinfectants or hemostatic agents (such as iodine tincture), it has a content of 1% or less. It should be administered with caution due to the possibility of side effects due to large doses and long-term operation, even when taken or injected, and it is used at a maximum daily dose of 100 mg or less. For these reasons, while iodine is expected to have various drug effects, an iodine preparation for ingestion or injection for treating cancer or AIDS for them has not yet been developed.
[0006]
[Patent Document 1]
Japanese Patent Application Laid-Open No. 9-40563 [Patent Document 2]
Japanese Patent Application Laid-Open No. 2001-122790 [Patent Document 3]
JP-A-6-172192 [Non-Patent Document 1]
"About the concept of taking stable iodine agents in the event of a nuclear disaster"
April 2002 Nuclear Safety Commission Special Committee on Disaster Prevention for Nuclear Facilities [Non-Patent Document 2]
Journal of the Japan Cancer Therapy Association, March 1994 issue [0007]
[Problems to be solved by the invention]
An object of the present invention is to develop a liquid iodine preparation which has an anti (or killing) virus and cancer therapeutic effect and has no side effects such as iodine poisoning or can be orally administered as an injection.
[0008]
[Means for Solving the Problems]
The present inventors have conducted intensive studies in order to solve the above-mentioned problems. As a result, 1) In the case of oral ingestion, a liquid containing 1.0 to 1.5% by weight of sodium iodide as an iodine component, It has been found that, even if the daily intake exceeds 100 mg, there is no side effect (iodine poisoning) and an extremely high anticancer effect. 2) In the case of ingestion by injection, an injection solution for treating AIDS containing sodium iodide in an amount equivalent to 1.0% by weight to 1.5% by weight as an iodine component also has side effects even if the daily intake exceeds 100 mg. No iodine poisoning) and very high anti- (killing) AIDS virus effect.
[0009]
That is, the present invention provides a sodium iodide-containing preparation described in 1) below, a cancer prevention and treatment agent described in 2), and an AIDS prevention and treatment agent described in 3) below.
1) A sodium iodide-containing preparation comprising a weak alkaline solution containing 1.0% by weight to 1.5% by weight of sodium iodide as an iodine component.
2) A prophylactic and therapeutic agent for cancer comprising a weakly alkaline solution containing 1.0% by weight to 1.5% by weight of sodium iodide as an iodine component.
3) A prophylactic and therapeutic agent for AIDS comprising a weakly alkaline solution containing 1.0% by weight to 1.5% by weight of sodium iodide as an iodine component.
Hereinafter, the present invention will be described in detail.
[0010]
BEST MODE FOR CARRYING OUT THE INVENTION
A sodium iodide salt (purity: 99.99%) is mixed with alkaline ionized water which is electrolytic water generated by electrolysis of mineral water to prepare a sodium iodide solution. The pH of this solution is 7-8. In the present invention, a liquid preparation containing 1.0% as an iodine content prepared by adding 2.0 g of sodium iodide (1 g of iodine content and 1 g of sodium content) to the above alkaline ionized water (98.0 cc) was used. The solution was taken at 200 cc / day for the prevention or treatment of cancer, and 20 cc / day for the prevention or treatment of AIDS.
[0011]
In the sodium iodide-containing preparation of the present invention, various amino acids commonly added to liquid preparations, high caloricizing agents such as glucose or vitamin preparations, other stabilizing agents, as long as the action is not impaired, Addition of a soothing agent or a small amount of a coloring agent may be used at all.
Test Examples are shown below to explain that the sodium iodide-containing preparation of the present invention has a therapeutic effect on AIDS and cancer.
[0012]
[Test example]
Test Example 1: Cancer therapeutic effect test Using the sodium iodide-containing preparation of the present invention prepared as described above, a cancer therapeutic effect test was performed under the following conditions. Table 1 shows the results of the test.
1) Study patient: Female, 42 years old 2) Disease name: Breast cancer on right side (Skills tumor: about 4 cm in diameter)
3) Administration method: 50 cc of iodine solution for cancer treatment 4 times a day (200 cc / day) 4) Study period: 17 months
[Table 1]
As is clear from the results in Table 1, CEA (standard low 0.0 to standard high 5.0), which is an adenocarcinoma tumor marker, was administered from 14.5 to 5.2 after 17 months (long term) administration. Meanwhile, CA19-9 (low reference value 0.0 to high reference value 37.0) sharply decreased from 1,077 to 53, decreased to near the reference value, and no metastasis of cancer was observed. Three months later, a CT scan revealed that the breast tumor, which had a diameter of 4 cm, had shrunk to about 2 cm, and that the breasts that had spread on the pan were restored to normal.
In addition, the patient goes through normal daily activities during the test period, and his physical condition improves. Blood test values (blood protein, leukocytes, liver function index, etc.) maintain normal values, and side effects (iodine poisoning) occur. Was also not recognized.
[0015]
Test Example 2: AIDS treatment test An AIDS treatment test was performed using the sodium iodide-containing preparation of the present invention prepared as described above under the following conditions. Table 2 shows the results of the test.
1) Measurement method: Bayer HIV-1 RNA 3.0 Assay (bDNA) method 2) Study patient: male, age 24 3) Medication: intravenous injection of 20 cc / day of iodine agent for AIDS treatment 4) Study period: 20 days ]
[Table 2]
As is evident from the results in Table 2, the administration of 20 days resulted in a significant decrease in the HIV-RNA (gene) of almost 50% (a virucidal effect) (the amount of HIV particles was 1/1 of Table 1). 2). No signs such as side effects were observed during and after the administration for 20 days.
[0018]
Test Example 3: Animal Toxicity Test A toxicity test in rats was performed under the following conditions.
1) Test substance: iodine preparation (dose 2 ml / Kg x body weight), control substance: purified water 2) Animal used: 10 SPF rats 3) Observation period: 14 days 4) Measurement method: general condition observation and body weight value- Bartlett test, risk factor 10% or less The results are as follows: (1) No animals died and no abnormalities were observed in the general condition. (2) Comparative analysis of test and control substances by one-way analysis of variance. There is no significant difference in weight change.
These results, toxicity of sodium iodide-containing formulations of the present invention is very low, the LD 50 values (acute toxicity) was judged to exceed 2000 mg / Kg.
[0019]
【The invention's effect】
As described in detail above, according to the present invention, despite the iodine content exceeding conventional iodine preparations, extremely low side effects, and further, an epoch-making AIDS treatment effect and cancer treatment which can be injected or orally administered. A novel iodine-containing formulation having an effect has been provided.
Therefore, the sodium iodide-containing preparation of the present invention has high safety and is expected to have a great effect on the prevention and treatment of cancer and AIDS.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003114498A JP2004315470A (en) | 2003-04-18 | 2003-04-18 | Pharmaceutical preparation containing sodium iodide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003114498A JP2004315470A (en) | 2003-04-18 | 2003-04-18 | Pharmaceutical preparation containing sodium iodide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2004315470A true JP2004315470A (en) | 2004-11-11 |
Family
ID=33474074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003114498A Pending JP2004315470A (en) | 2003-04-18 | 2003-04-18 | Pharmaceutical preparation containing sodium iodide |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2004315470A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005089780A1 (en) * | 2004-03-18 | 2005-09-29 | Umeda Jimusho Ltd. | Composition against aids virus and method of selectively inactivating virus-infected cells |
| WO2012042587A1 (en) * | 2010-09-27 | 2012-04-05 | 中村 博 | Hydrogen iodide-containing health food and hydrogen iodide-containing drug, and method for producing same |
| JP2020152683A (en) * | 2019-03-20 | 2020-09-24 | 株式会社ユーアイナ | Cancer treatment method using analysis of peripheral blood circulation tumor cells |
| WO2021198938A1 (en) * | 2020-03-31 | 2021-10-07 | タイ ミン ファーマシューティカルズ ジェイエスシー | Diisopropylamine compound and iodine for treating cancer, endometriosis and pain in patients with cancer or endometriosis |
| CN116407555A (en) * | 2023-01-18 | 2023-07-11 | 北京大学 | EGFR protein phosphorylation inhibition reagent, inhibition method and application |
| KR20240039868A (en) | 2022-09-20 | 2024-03-27 | 한국유나이티드제약 주식회사 | Pharmaceutical composition for thyroid protection and manufacturing method thereof |
| JP2024544343A (en) * | 2021-12-22 | 2024-11-28 | ローラ・マン・ケヴェハジ | Herbal Composition for Breast Cancer Prevention |
-
2003
- 2003-04-18 JP JP2003114498A patent/JP2004315470A/en active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005089780A1 (en) * | 2004-03-18 | 2005-09-29 | Umeda Jimusho Ltd. | Composition against aids virus and method of selectively inactivating virus-infected cells |
| WO2012042587A1 (en) * | 2010-09-27 | 2012-04-05 | 中村 博 | Hydrogen iodide-containing health food and hydrogen iodide-containing drug, and method for producing same |
| JP2020152683A (en) * | 2019-03-20 | 2020-09-24 | 株式会社ユーアイナ | Cancer treatment method using analysis of peripheral blood circulation tumor cells |
| JP7603270B2 (en) | 2019-03-20 | 2024-12-20 | 株式会社セルクラウド | Cancer treatment method using analysis of circulating tumor cells in peripheral blood |
| WO2021198938A1 (en) * | 2020-03-31 | 2021-10-07 | タイ ミン ファーマシューティカルズ ジェイエスシー | Diisopropylamine compound and iodine for treating cancer, endometriosis and pain in patients with cancer or endometriosis |
| JP2024544343A (en) * | 2021-12-22 | 2024-11-28 | ローラ・マン・ケヴェハジ | Herbal Composition for Breast Cancer Prevention |
| JP7797660B2 (en) | 2021-12-22 | 2026-01-13 | ローラ・マン・ケヴェハジ | Herbal compositions for breast cancer prevention |
| KR20240039868A (en) | 2022-09-20 | 2024-03-27 | 한국유나이티드제약 주식회사 | Pharmaceutical composition for thyroid protection and manufacturing method thereof |
| CN116407555A (en) * | 2023-01-18 | 2023-07-11 | 北京大学 | EGFR protein phosphorylation inhibition reagent, inhibition method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2314810C2 (en) | Method for treatment using medicinal formulations containing pharmaceutical compositions of 5,8,14,-triazatetracyclo[10.3.1.0 (2,11).0(4,9)]hexadeca-2( 11),3,5,7,9-pentaene | |
| JP4885877B2 (en) | A preventive mixture for simultaneous decontamination of radioactive cesium (*Cs), radioactive strontium (*Sr), and radioactive iodine (*I) from the in vivo environment of affected subjects | |
| CN101987111A (en) | Composition of cisplatin in combination with 2,2'-dithio-bis(ethanesulfonate) (dimesna) | |
| EP0139534B1 (en) | Compositions for the prophylactic treatment of osteitis and osteomyelitis | |
| MXPA01004980A (en) | Use of paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby. | |
| US6063814A (en) | Phorbol esters as anti-neoplastic and white blood cell elevating agents | |
| JPH0296524A (en) | Treatment drug composition having anti-cancer activity and cancer treatment method | |
| WO1991002529A2 (en) | Product and method for killing abnormal vertebrate cells | |
| JPH06505231A (en) | Use of quinones in the treatment of cancer or AIDS | |
| JPH10139670A (en) | Interleukin 12 inducer and pharmaceutical composition | |
| JP2004315470A (en) | Pharmaceutical preparation containing sodium iodide | |
| KR950008767B1 (en) | Novel pharmacentical use of ebselen | |
| AU662883B2 (en) | Use of trinitrobenzenes or carminic acid in the treatment of cancer or viral diseases | |
| HU190072B (en) | Process for production of medical preparatives with sinergetic influence | |
| JP2025015727A (en) | Injection solution containing p-boronophenylalanine | |
| JPS6379824A (en) | Carcinostatic agent | |
| WO1991017751A1 (en) | Orally administrable gallium compositions and methods of treatment therewith | |
| US5432187A (en) | Benzimidazole anthelmintic in the treatment of microsporidial infections | |
| JP2010265209A (en) | Iodo liquid formulation | |
| EP1524273A1 (en) | Process for the preparation of trans- or cis-diammoniumdichlorodihydroxyplatinum(IV) salts and derivatives and their use for the preparation of pharmaceutical active agents | |
| JP2021172643A (en) | Iodine-based liquid preparation and method for producing the same | |
| EP0372676A1 (en) | Therapeutic preparation and method | |
| JP2008143808A (en) | Liquid preparation containing high-concentration colloidal organic iodine, and method for producing the same | |
| JP2003507334A (en) | Plasma substitute composition | |
| RU2192870C1 (en) | Antiviral composition, method of its active component preparing and method of treatment of hiv-infected patients with said composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060412 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20060927 |
|
| A521 | Written amendment |
Effective date: 20060928 Free format text: JAPANESE INTERMEDIATE CODE: A821 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090909 |
|
| A02 | Decision of refusal |
Effective date: 20100113 Free format text: JAPANESE INTERMEDIATE CODE: A02 |